High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Liu, Furong ^a   Zhang, Yaojun ^a   Peng, Zhenwei ^a   Gao, Hengjun ^a   Xu, Li ^a   Chen, Minshan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Hepatectomy; Hepatocellular carcinoma; High mobility group box 1; Prognosis; Prognostic factor

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; FEMALE; HEPATECTOMY; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84863104777     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-135     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. 10.1002/hep.20933, 16250051.
3. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005, 40:225-235. 10.1007/s00535-005-1566-3, 15830281.
4. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219. 10.1016/S1535-6108(04)00058-3, 15050913.
5. Bustin M, Hopkins RB, Isenberg I. Immunological relatedness of high mobility group chromosomal proteins from calf thymus. J Biol Chem 1978, 253:1694-1699.
6. Luan ZG, Zhang H, Yang PT, Ma XC, Zhang C, Guo RX. HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. Immunobiology 2010, 215:956-962. 10.1016/j.imbio.2009.11.001, 20163887.
7. Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequencespecific transactivation from the human Bax gene promoter. J Biol Chem 2002, 277:7157-7164. 10.1074/jbc.M110233200, 11748232.
8. Zayed H, Izsvák Z, Khare D, Heinemann U, Ivics Z. The DNA-bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res 2003, 31:2313-2322. 10.1093/nar/gkg341, 154227, 12711676.
9. Naghavi MH, Nowak P, Andersson J, Sönnerborg A, Yang H, Tracey KJ, Vahlne A. Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology 2003, 314:179-189. 10.1016/S0042-6822(03)00453-7, 14517071.
10. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195. 10.1038/nature00858, 12110890.
11. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008, 68:4026-4030. 10.1158/0008-5472.CAN-08-0427, 18519658.
12. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005, 106:609-616. 10.1182/blood-2004-10-3906, 15802534.
13. Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, Habiel DM, Miller F, Jiang HP, Li J, Pardi R, Palumbo R, Olivotto E, Kew RR, Bianchi ME, Marcu KB. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J Immunol 2010, 184:4497-4509. 10.4049/jimmunol.0903131, 2915896, 20231695.
14. Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, Anwar T, Rosa R, Indelicato M, Fini M, Pucci B, Russo MA. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis 2011, 32:1167-1175. 10.1093/carcin/bgr101, 21642357.
15. Yang J, Chen L, Yang J, Ding J, Rong H, Dong W, Li X. High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep 2011, : . in press.
16. Qin YH, Dai SM, Tang GS, Zhang J, Ren D, Wang ZW, Shen Q. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol 2009, 183:6244-6250. 10.4049/jimmunol.0900390, 19890065.
17. Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010, 1799:131-140. 10.1016/j.bbagrm.2009.11.014, 2818552, 20123075.
18. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010, 136:677-684. 10.1007/s00432-009-0706-1, 19898867.
19. Bao G, Qiao Q, Zhao H, He X. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol 2010, 8:52. 10.1186/1477-7819-8-52, 2909949, 20579387.
20. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008, 216:167-175. 10.1002/path.2391, 18680137.
21. Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P, Qi L, Hu G, Tian Y, Qiu Y. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 2010, 46:3007-3015. 10.1016/j.ejca.2010.07.016, 20724142.
22. Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res 2012, 18:293-298. 10.1007/s12253-011-9442-3, 21953322.
23. Edge SB, Carducci MA, Compton CC, et al. AJCC cancer staging manual 2009, 237. Springer, Chicago, 7.
24. Peng RQ, Wu XJ, Ding Y, Li CY, Yu XJ, Zhang X, Pan ZZ, Wan DS, Zheng LM, Zeng YX, Zhang XS. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO + T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer 2010, 10:496. 10.1186/1471-2407-10-496, 2949807, 20846416.
25. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008, 40:446-452. 10.1016/j.dld.2007.11.024, 18294942.
26. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342. 10.1038/nri1594, 15803152.
27. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 2010, 107:12611-12616. 10.1073/pnas.1006542107, 2906549, 20616036.
28. Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett 2011, 313:91-98. 10.1016/j.canlet.2011.08.028, 21945853.
29. Liu Z, Falo LD, You Z. Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol 2011, 187:118-125. 10.4049/jimmunol.1003378, 3119781, 21642542.